An immunological model of HIV-1 infection that accounts for antiretroviral drug uptake via explicit compartments is considered. Different from traditional methods where the drug effects is modeled implicitly as a proportional inhibition of viral infection and production, in this paper, it is assumed that the CD4 + T cells can 'prey on' the antiretroviral drugs and become the cells which cannot be infected or produce new virions. Drug dymamics is modeled applying impulsive differential equations. The basic reproductive number R 0 is defined via the next infection operator. It is shown that with perfect adherence the virus can be eradicated permanently if R 0 is less than unity, otherwise, the virus can persist by applying persistent theory. The effects of imperfect adherence are also explored. The results indicate that even for the same degree of adherence, different adherence patterns may lead to different therapy outcomes. In particular, for regular dosage missing, the more dosages are consecutively missed, the worse therapy outcomes will be.
Introduction
Human Immunodeficiency Virus (HIV) is a disease that causes depletion of CD4 + T cells and can be transmitted by blood or other body fluids [13, 15, 29] . Until recently, there are four classes of antiretroviral (ARV) drugs available for treating HIV-1 infected patients: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and entry/fusion inhibitors (EIs) [8, 19] . Antiretroviral therapy (ART) containing a combination of three or more drugs chosen from two or more classes has proven to be highly effective in reducing the viral load of HIV infected patients.
There are many mathematical models developed to describe the antiretroviral therapy [4, 8, 16, 17, 27] and papers therein. In most of these models, the drug therapy is described by the treatment effect (drug efficacy), which is often assumed to be constant or determined by the plasma drug concentration via the E max model [8, 27] . Our previous work in [30] considered that during drug administration intervals drug concentration varies periodically so as to incorporate the drug dynamics. However, we simplified the model by applying a nonnegative periodic function to represent the drug effects while ignoring the dynamics of drug behavior, which may have a significant impact on certain outcomes [22] .
In this paper, we extend the work in [30] by incorporating the drug dynamics into the HIV viral dynamical model via explicit compartments, that is, the CD4 + T cells can 'prey on' the antiretroviral drugs, such that T cells may be susceptible, infected or inhibited by drugs with the drug behavior modeled by impulsive differential equations. This leads to a hybrid system of continuous HIV viral dynamics and discontinuous drug dynamics. Smith and Wahl [23] considered such a model, and gave the long-term dynamics of HIV progression under extreme cases (the drug is administered sufficiently often or the dosage is sufficiently large). However, the authors did not give the full global dynamics of the hybrid system, partially due to the incorporation of the impulses. Hence, our first aim here is to give the threshold parameter (the basic reproductive number) which determines the extinction and the persistence of the virus and investigate the global dynamics of the hybrid system.
Adherence to prescribed ART is recognized as an essential principle in HIV treatment. Imperfect or partial adherence can facilitate the emergence of drug-resistant mutations [6, 15] . In order to determine regimens for partial adherence, a number of mathematical models have been developed to quantify how drug concentration levels in the body of an HIV patient affect viral replication [5, 7-9, 12, 15, 18, 21, 24, 25, 27] . However, most of these papers analyze single adherence pattern applying classical continuous viral dynamical model [3, 14] . Based on the importance of understanding the effects of adherence on therapy outcomes, our second aim here is to investigate how different adherence patterns and different degrees of adherence affects the CD4 + T cell counts and viral load applying the hybrid system.
Our main purpose is then to establish an immunological model of HIV infection incorporating antiretroviral therapy explicitly. We define the basic reproductive number R 0 applying the next generation operator and study the global dynamics and the persistence of the system. Meanwhile, we study how different degrees of adherence and different adherence patterns will affect the therapy outcomes so as to obtain optimal treatment protocol.
The rest of the paper is organized as follows. In next section, we study the global dynamics of the hybrid system. Then we numerically present how perfect and imperfect adherence (different adherence patterns and different degrees of adherence) affect viral progression in Section 3. We conclude and discuss the results in the final section.
The SIR-type model of PI-sparing therapy
In this section, we consider an SIR-type model with reverse transcriptase inhibitors or other drugs which prevent cellular infection adapted from [23] , and study the global dynamics. Note that we don't consider the loss for the virions during the infection.
R is the plasma drug concentration of the reverse transcriptase inhibitors, satisfying
We leave out the equation that represents the noninfectious virus dV NI /dt = n I (1 − ω)T I − d V V NI , since it can be decoupled from system (2.1).
In the equations, T S , T I denote the susceptible and infected CD4 + T cells, respectively, T R denotes the noninfected CD4 + T cells which have absorbed the reverse transcriptase inhibitors, cells cannot be infected in this state. V I and V NI denote the infectious and non-infectious virus respectively, n I is the number of virions produced per infected cell per day, ω is the fraction of virions which are infectious produced per day by an infected cell , d V is the rate at which free virus is cleared, r I is the infection rate of free virus, d S and d I are the death rates of noninfected and infected CD4 + T cells, and r R is the rate at which the drug inhibits the T cells. λ is the birth rate of CD4 + T cells, while m R is the rate at which the drug is cleared from the intracellular compartment. Refer to [15, 24] for detail descriptions.
We assume that drug is administered with time interval τ, drug dosage R i , and the drug is cleared with the rate d R . Solving the impulsive differential equations (2.2), we have that the plasma drug concentration ultimately reaches the steady state R * (t) (plateau plasma concentration) [2, 10] , which is globally asymptomatically stable, and equals
In the following, we will study the hybrid system of (2.1) and (2.2). It is obvious that any solution of system (2.1) with nonnegative initial values is nonnegative. Adding the first three equations of (2.1) we have
Hence,
Then by the fourth equation of (2.1) we have
We summarize these results in the following theorem. Theorem 2.1. The solutions of the hybrid system (2.1) and (2.2), with the initial value (T S0 , T R0 , T I0 , V I0 , R(0)) ∈ R 5 + are uniformly and ultimately bounded. Furthermore, the compact set J = {(T S , T R , T I , V I ) ∈ R 4 + , (T S , T R , T I , V I ) (π, π, π, π)} is positively invariant and attracts all positive orbits in R 4 + .
The definition for the basic reproductive number
In the following, we present the basic reproductive number R 0 for the hybrid system (2.1) and (2.2) according to the general procedure presented in [1, 28] and refer to Yang and Xiao [31] .
We start our analysis of systems (2.1) and (2.2) by demonstrating the existence of a periodic 'virus-free' limit cycle. Eqs. (2.1) admit the following solution T I = V I = 0, with T S and T R dynamics satisfying
Adding the two equations of system (2.4), we get
Hence, there holds T S + T R → λ/d S , as t → ∞. Since we consider the long term dynamics of the virus, we substitute λ/d S − T S for T R , and meanwhile, we apply the plateau plasma drug concentration, then by the first equation we have
System (2.5) admits a globally stable periodic solution which gives
Hence we get the periodic 'virus-free' solution of system (2.1), that is,
Then we define two matrices similar to the next generation matrices.
Let Y(t, s), t s be the evolution operator of the linear τ-periodic system
That is, for each s ∈ R, the 2 × 2 matrix Y(t, s) satisfies
where I is a 2 × 2 identity matrix. Define the next infection operator L,
where C ω is defined as the ordered Banach space of all τ-periodic functions from R to R 2 , equipped with the maximum norm . , and the positive cone C + ω := {φ ∈ C ω : φ(t) 0, ∀t ∈ R}, φ(s) is the initial distribution of the infected CD4 + T cells and the virus.
Note that F(s)φ(s) is the distribution of the new infections produced by the infected ones introduced at time s. Y(t, s)F(s)φ(s), t s then gives the distribution of the infected individuals who were newly infected at time s and remain infected at time t. Then the limit gives the distribution of accumulative new infections at time t which are produced by all those infected individuals φ(s) introduced at previous time to t.
Then according to Wang and Zhao [28] , we define the basic reproductive number as the spectral radius of L, that is,
In order to characterize R 0 , we consider an auxiliary linear τ-periodic system
with χ ∈ (0, ∞), and W(t, s, χ) is the evolution operator of system (2.6), t s, s ∈ R. ρ(W(τ, 0, χ)) is the spectral radius of the monodromy matrix W(τ, 0, χ). We have the following two results, which will be used in our numerical computation of R 0 and the proof of our main results in Section 2.2.
Lemma 2.2. The following statements are valid.
Lemma 2.3. The following statements are valid.
The 'virus-free' periodic solution (T S (t),T R (t), 0, 0) is asymptotically stable if R 0 < 1, and unstable if R 0 > 1.
If the drug concentration R(t) is given by the average plasma drug concentration R av , which is defined as
then system (2.1) is an autonomous system. And the 'virus-free' equilibrium equals
In this case, F(t) ≡ F, ∀t 0. The use of next generation matrix [26] yields the expression for the basic reproductive number
We have the following remark. Remark 2.4. The basic reproductive number of the time-averaged autonomous system of the periodic system (2.1) will underestimate infection risk.
We illustrate as the drug administration interval varies, how the basic reproductive number of the time-averaged autonomous system, [R 0 ], given in (2.7) and the basic reproductive number R 0 , calculated applying Lemma 2.2, change. From Figure 1 , we can see that the average basic reproductive number [R 0 ] is always smaller than the basic reproductive number R 0 when the drug administration interval τ varies ranging from 0.2 day to 1 day. This implies that the risk of infection will be underestimated if the average basic reproductive number is used. [23, 24] and references therein.
Threshold dynamics
In this section, we show that the basic reproductive number serves as a threshold parameter that determines the global dynamics. Theorem 2.5. If R 0 < 1, then the 'virus-free' periodic solution P 0 = (T S (t),T R (t), 0, 0) is globally asymptotically stable.
Proof. The local stability of the 'virus-free' periodic solution P 0 when R 0 < 1 is satisfied by Lemma 2.3. Now it is sufficient to prove that P 0 is globally attractive if R 0 < 1.
The plasma drug concentration ultimately reaches the steady state (the plateau drug concentration) R * (t), Eq. (2.3). Then we can choose an integer n 1 great enough and t 1 n 1 τ, such that for t t 1 , by the first two equations of system (2.1) and the positivity of the solutions for (2.1), we have
The corresponding comparison system Eq. (2.4) admits a globally stable periodic solution (T S (t),T R (t)).
Then by the comparison principle, there exists a time t 2 > t 1 , and > 0, such that T S (t) T S (t) + , T R (t) T R (t) + , t t 2 . By the third and forth equations of system (2.1), for t t 2 , we have
Consider an auxiliary system
where z = (z 1 , z 2 ) T , and the matrix
By Zhang and Zhao [32] (Lemma 2.2), it follows that there exits a positive, τ-periodic function v(t), such that z(t) = e µ 1 t v(t) is a solution of system (2.9), where
is continuous for small , we can choose small enough such that ρ(Φ (F−V+ M) (τ)) < 1, that is µ 1 < 0. Therefore, we have z(t) → 0, as t → ∞. For any nonnegative initial value (T I (t 2 ), V I (t 2 )) T of system (2.8), there exits a z * large enough such that
Hence, we have T I (t) → 0, V I (t) → 0 as t → ∞. By the fist and second equations of system (2.1), we have T S (t) →T S (t), T R (t) →T R (t) as t → ∞. We get the global asymptotical stability of the 'virus-free' periodic solution. This completes the proof. In order to better understand the proof of the following theorem for the readers, we present some notations and a lemma first.
Define
, ∂X 0 := X\X 0 . Let P : X → X be Poincaré map associated with system (2.1), satisfying P(x 0 ) = u(τ, x 0 ), ∀x 0 ∈ X, u(t, x 0 ) is the unique solution of (2.1) with u(0, x 0 ) = x 0 . It can be seen easily that
Clearly, the fixed point of the Poincaré map P in X is M 1 = (T S (0),T R (0), 0, 0). Lemma 2.6. If the basic reproductive number R 0 > 1, then there exists a δ 0 > 0 such that for all x 0 ∈ X 0 with x 0 − M 1 δ 0 , where
Proof. By the continuity of solutions with respect to the initial values, ∀ > 0 there exists δ 0 > 0 such that for all x 0 ∈ X 0 with x 0 − M 1 δ 0 , there holds u(t, x 0 ) − u(t, M 1 )) , ∀t ∈ [0, ω]. We further claim that Eq. (2.10) holds. Assume, by contradiction, that (2.10) does not hold. Then we have lim sup
for some x 0 ∈ X 0 . Without loss of generality, we assume that d(P m (x 0 ), M 1 ) < δ 0 for all m 0. It follows that
For any t 0, let t = mω + t , where t ∈ [0, ω] and m = [ t ω ] is the greatest integer less than or equal to t ω . Thus, we get
Note that (T S (t), T R (t), T I (t), V I (t)) = u(t, x 0 ). It then follows that T I (t) < , V I (t) < , ∀t 0. Then from the first and second equations of (2.1), we have
Consider an auxiliary equation
For any > 0, system (2.11) admits a globally attractive solution (T S (0, ),T R (0, )). Then for any ξ > 0, there exists t 3 > 0 such thatT
is any solution of (2.11). Note thatT S (0, ) →T S (t),T R (0, ) →T R (t) as → 0. Then for anyη > 0 there exists¯ > 0 such thatT S (0, ) T S (t) −η,T R (0, ) T R (t) −η for <¯ . It follows that for t t 3 and small enough ( <¯ )T
Then the comparison principle indicates that T S (t) T S (t, ) T S (t) − η for t t 3 and small enough.
Consider another auxiliary system
By Zhang and Zhao [32] (Lemma 2.2), we know that there exists a positive, τ-periodic function p(t) = (p 1 (t), p 2 (t)), such that e µ 2 t p(t) is a solution of system (2.12), where
is continuous for small η and ρ(Φ F−V (τ)) > 1, we can choose η small enough such that ρ(Φ F−V−ηM (τ)) > 1, that is µ 2 > 0. Let t = nτ > t 3 , and n be nonnegative integer, we get
For any negative initial values (T I (t 3 ), V I (t 3 )) T of the comparison system of (2.12), there exits a sufficiently small z * > 0, such that (
By the comparison theorem, we have (T I (t), V I (t)) T z * e µ 2 (t−t 3 ) (T I (t − t 3 ),V I (t − t 3 )) T for all t t 3 . Thus we obtain T I (nτ) → ∞, V I (nτ) → ∞, as n → ∞, a contradiction. Hence Eq. (2.10) holds. This completes the proof. 
and system (2.1) admits at least one positive periodic solution.
Proof. In the following we will show that P is uniformly persistent with respect to (X 0 , ∂X 0 ). Due to the uniform and ultimate boundedness of the solutions of system (2.1), the Poincaré map P admits a global attractor in X. For any (T S0 , T R0 , T I0 , V I0 ) ∈ X 0 , the first equation of system (2.1) can be written as
Then we have
By the second equation of system (2.1) we can deduce that T R (t) > 0 for all t > 0. Furthermore, by Theorem 4.1.1 in [20] as generalized to nonautonomous systems, the irreducibility of the cooperative matrix
implies that T I (t) > 0, V I (t) > 0 for all t > 0. Thus, both X and X 0 are positively invariant. Clearly, ∂X 0 is relatively closed in X.
We now show that
14)
It suffices to prove that for any
which contradicts with the assumption that (T S0 , T R0 , T I0 , V I0 ) ∈ M ∂ , hence (2.14) holds. Clearly, there is exactly one fixed point of P in M ∂ , which is M 1 = (T S (0),T R (0), 0, 0). Lemma 2.6 implies that M 1 is isolated in X and W s (M 1 ) ∩ X 0 = ∅. Clearly, each orbit in M ∂ converges to M 1 , and M 1 is acyclic in M ∂ . By Theorem 1.3.1 in [33] , it follows that P is uniformly persistent with respect to (X 0 , ∂X 0 ). By Theorem 3.1.1 in [33] the solutions of (2.1) are uniformly persistent.
Furthermore, Theorem 1.3.6 in [33] implies that P has a fixed point
Suppose not, by the periodicity of T * S (t) and T * R (t), there holds T * S (t) ≡ 0, T * R (t) ≡ 0 for all t 0. Then adding the first two equations of (2.1), we have 0 < λ = 0, a contradiction. The first equation of system (2.1) can be written as
Thus T * S (t) > 0 for all t 0 by the periodicity. By the second equation of system (2.1) we can deduce that T * R (t) > 0 for all t 0. Furthermore, by Theorem 4.1.1 in [20] as generalized to nonautonomous systems, the irreducibility of the cooperative matrix [11] 
) is a positive periodic solution of system (2.1). This completes the proof.
Numerical simulations
We consider two therapy strategies. To model imperfect adherence, let p denote the fraction of the prescribed doses of the drug which are taken. Now a natural question arises: given the same degree of adherence, how will different adherence patterns affect viral dynamics and long-term prediction of therapy? We attempt to address this question in the following. In Figure 4 , we present four adherence patterns with the same value of p = 0.5. Figure 4 (a) shows the plasma drug concentration when every other dose is missed (Pattern 1). Pattern 2 shows two doses are taken followed by two doses missed. Pattern 3 shows three doses are taken followed by three doses missed and Pattern 4 shows five doses are taken followed by five doses missed. Patterns 1-4 describe different adherence patterns by the block size, which is defined as the number of consecutive doses taken or missed each time a dose is taken or missed [8, 27] .
We present in Figure 5 the time evolution of the total non-infected T cells, the infected T cells, and the viral load for Pattern 1 to Pattern 4 with adherence p = 0.5. With perfect adherence, the virus will be eliminated from the host, see from Figure 2 . For imperfect adherence, from Figure 5 we can see clearly that Pattern 1 performs better than the other patterns with three or five consecutive missed doses in keeping the total non-infected T cells at a higher level, while keeping the infected T cells and the viral load at relatively lower levels. This indicates that smaller block size performs better in reducing viral load. The adherence patterns we have considered are regular. Note that for the same degree of adherence p = 0.5, there are other adherence patterns, some of which may be irregular. We do not consider these irregular patterns, for they will lead to non-periodic systems such that the analytical results cannot be applied. Further studies may be focused on some numerical results.
When the degree of adherence p varies, numerical simulations indicate that with regular drug dosages 'taken and missed', as the adherence p increases, drug therapy performs better in reducing viral load at lower levels. For example, drugs that are taken five doses followed by five consecutive missed doses (according to p = 1/2) perform better than drug that is taken one dose followed by two doses missed (according to p = 1/3) (figures are not shown).
Conclusions and discussions
In this paper, we consider an immunological model for HIV viral dynamics incorporating the effects of the reverse transcriptase inhibitors explicitly. There are many authors considering HIV drug therapy implicitly [4, 8, 16, 17, 27] . In those classical models, the effects of the drugs are assumed to reduce the infection rate (PI sparing therapy) by a fraction 1 − n rt , where n rt is assumed to be the drug efficacy. The basic reproductive number in this case is then
If the drug is explicitly modeled as that in system (2.1), we consider the case when the drug varies with sufficiently small amplitude, that is the drug concentration can be seen as a constant, i.e., R(t) ≡ R, ∀t 0. Then the basic reproductive number yields
From the expressions for the basic reproductive numbers we can see that when the drug is implicitly modeled, it acts to reduce the infection rate r I , while if the drug is explicitly modeled, that is, the T cells may be susceptible, infected or inhibited by the drug, in this case since the uninfected T cells T S will absorb the drug and become cells T R which cannot be infected further, then the susceptible T cells will be reduced by a fraction (d S + m R )/(d S + m R + r R R). Hence, the implicit model and the explicit model act in different ways to reduce the number of T cells that will be infected by free virus.
Our main results show that for perfect adherence, the virus-free periodic solution of system (2.1) is globally asymptotically stable if R 0 < 1, whilst the virus is persistent if R 0 > 1, and meanwhile there exists a positive periodic solution, which is globally asymptotically stable numerically. Since the basic reproductive number R 0 is the function of the drug dosage R i and the drug administration interval τ, hence we can design the regimen strategy to ensure the elimination of the virus theoretically.
For imperfect adherence, different degrees of adherence and different adherence patterns will affect therapy outcomes differently. Given the same degree, smaller blocking size performs better in reducing viral load. With regular dosages taken and missed, the bigger the degree of the adherence, the better the therapy outcome will be.
